The last patent held by Atrovent Hfa is set to expire on 17 January, 2030. Following this expiry, it will be possible for other manufacturers to produce Atrovent Hfa generic versions, potentially offering more cost-effective treatment options to patients.
Atrovent Hfa is typically prescribed to treat various respiratory conditions, including chronic obstructive pulmonary disease (COPD). The active ingredient, ipratropium bromide, aids in opening the airways by relaxing the muscles around your airways.
Atrovent Hfa holds a patent, titled 'Inhaler device', set to expire on 17 January, 2030. Post this date, the advent of Atrovent Hfa generic versions is expected. Below are the details of the patent: